Plus Therapeutics Stock
Plus Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Marc H. Hedrick
- Employees
- 28
- Market cap
- $9 M
- IPO
- 11/07/2001
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented…
Plus Therapeutics stock: price history
1D
+6.0%
1W
+1.0%
1M
-7.0%
6M
-32.1%
YTD
-69.8%
1Y
-68.0%
2Y
-91.4%
5Y
-99.5%
10Y
-100.0%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~5% stronger price swings than usual
Ask the agents about Plus Therapeutics
Analyst assessment of Plus Therapeutics
PRICE TARGET LOW
US$25.00
CONSENSUS
US$25.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 08/06/2026
Plus Therapeutics stock metrics
P/E
-0
P/B
4.8
EV/EBITDA
-0.31
RETURN ON EQUITY
-164.9%
NET MARGIN
-2,191.2%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
2,413,596
AVG. DAILY VOLUME (30D)
176,171
Insider transactions (SEC)
Clowes Howard
HEDRICK MARC H
HEDRICK MARC H
HEDRICK MARC H
van Es-Johansson An
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Plus Therapeutics stock
What does Plus Therapeutics do?
Plus Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Marc H. Hedrick, the company employs around 28 people.
The IPO was on 11/07/2001; the stock trades on NASDAQ under the ticker PSTV.
What do analysts say about Plus Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 08/06/2026).
The average price target is US$25.00, ranging from US$25.00 to US$25.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Plus Therapeutics report next?
Around past earnings, price swings were roughly 5% stronger than usual.
Does Plus Therapeutics pay a dividend?
No, Plus Therapeutics currently does not pay a dividend.
Which stocks are comparable to Plus Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Plus Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Plus Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.